Under construction – not a live service
Sign in
Taking people in EgyptPhase 3

Tests nicorandil for inflammation in rheumatoid arthritis

Tests nicorandil tablets for inflammation in adults with active rheumatoid arthritis.

Plain-language title generated from the registry record
Registry title: Nicorandil as Anti-inflammatory in Rheumatoid Arthritis

Key facts

Where
Tanta, EgyptSee the site
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Source: NCT07516769, who can take part

Where in Egypt

  • Tanta universityTanta, EgyptTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Tanta University
Trial code
NCT07516769
Record updated
18 June 2026
Original description
This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.Read full original descriptionShow less

Clinical Study Evaluating the Effect of Nicorandil as Anti-inflammatory and Immune Modulatory in Patients With Rheumatoid Arthritis

This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.

Inclusion: Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) i.e., 28 joints disease activity score (DAS-28) >2.6; Patients receiving the conventional DMARDs.

Exclusion: Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs; Patients receiving oral prednisolone greater than 15mg/day; Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis; Patients with hypersensitivity to study medications; Patients using antioxidants; Pregnant and lactating females.

ClinicalTrials.gov NCT07516769